研究关注:Biosion’s BSI-737 exerts strong antitumor activity
Biosion Inc. recently presented preclinical data describing their B7H3/PD-L1 bispecific antibody-drug conjugate (ADC) BSI-737 for the treatm...
## 事件概览
Biosion Inc. recently presented preclinical data describing their B7H3/PD-L1 bispecific antibody-drug conjugate (ADC) BSI-737 for the treatm...
## 核心信息
Biosion Inc. recently presented preclinical data describing their B7H3/PD-L1 bispecific antibody-drug conjugate (ADC) BSI-737 for the treatment of cancer.
## 为什么值得关注
这条内容与 cancer 相关,可能影响科研选题、技术趋势判断或产业观察。BioDir 已根据来源、摘要长度、主题词和潜在影响给出 40 分的候选评分。
## 发布提示
发布前应核对原文链接、研究对象、样本规模、方法限制和结论边界。若来源为 bioRxiv 或 medRxiv,应明确标注其为预印本,尚未经过同行评议。